TRUMP’S HEALTH SECRETARY NOMINEE IS AN ESTABLISHMENT BIG PHARMA EXEC

Happy to announce, I am nominating Alex Azar to be the next HHS Secretary. He will be a star for better healthcare and lower drug prices!
— Donald J. Trump (@realDonaldTrump) November 13, 2017

President Trump has nominated a former lobbyist and executive of a major pharmaceutical company to be U. S. Health Secretary.
On Monday, Trump announced his pick for Secretary of the Department of Health and Human Services. ‘Happy to announce, I am nominating Alex Azar to be the next HHS Secretary. He will be a star for better healthcare and lower drug prices,’ Trump tweeted. The nominee immediately came under scrutiny for his former connections to the pharmaceutical industry.
Azar formerly served as U. S. Deputy Secretary of Health and Human Services under George W. Bush from 2005 to 2007. In June 2007, Azar began working as a lobbyist for pharmaceutical giant Eli Lilly and Company. Azar also served as Eli Lilly’s spokesman as its Senior Vice President of Corporate Affairs and Communications. Beginning January 1, 2012, Azar was promoted to President of Lilly USA, LLC, the largest division of Eli Lilly and Company – a position which put him in charge of Eli Lilly’s entire U. S. operation.

This post was published at The Daily Sheeple on NOVEMBER 15, 2017.

Doctor Charged For Opioid Deaths In Oklahoma

As the opioid epidemic spirals out of control, and more die on the streets in Big Pharma’s war on us, many are becoming aware of the cause of the crisis. One doctor in Oklahoma is now facing justice for over prescribing the medications that lead to the death of five of her patients.
An Oklahoma doctor was charged Friday with second-degree murder in the overdose deaths of at least five patients from the powerful painkillers and other drugs she prescribed, often in combinations that made up an addict’s ‘holy trinity’ of pills, state investigators said.
Oklahoma’s attorney general announced five second-degree murder counts against Regan Nichols, whose patients died while she worked at a Midwest City clinic. An Oklahoma County judge also issued a warrant for her arrest. But Nichols isn’t the only doctor in trouble for the epidemic. Although this crisis could be traced back to Big Pharma and their lobbying the government for privileges, doctors seem to be taking the fall for their refusal to say ‘no’ the pushy and disingenuous pharmaceutical companies.
Opioids, which are primarily prescription painkillers and heroin, were factors in more than 33,000 deaths across the U. S. in 2015, and opioid overdoses have more than quadrupled since 2000, according to the U. S. Centers for Disease Control and Prevention.

This post was published at The Daily Sheeple on June 25, 2017.

Big Pharma and the FDA vs. Nutritional Supplements

“While the idea of admitting that a bureaucracy is necessary, I must also admit that marketers are liars and if left unregulated will rival politicians in their dishonesty when making product claims. Both admissions shake my libertarian sensibilities to the core.”
First, a free market eventually corrects for the condition of “marketers are liars,” unlike with politicians. Furthermore, not ALL marketers are liars.
Second, what makes you think the FDA, or any government bureaucracy for that matter, doesn’t lie? If one thinks we need an FDA, then one should think that we also need an EPA, FED, NLRB, EEOC, and on, and on, and on … further violating your libertarian sensibilities.
The head administrator of the FDA is pretty much a revolving door with Big Pharma:
is government regulation always the knee jerk reaction to every ill that affects society? Can you creatively think of some other solutions that don’t violate the Constitution of the United States? Keep reading, and maybe some other ideas will present themselves.
More people die every year from legalized drugs than from taking supplements, not to mention the drugs the FDA eventually gets around to recalling, after they’ve already done their damage. In addition, the FDA is continually pushed by vested interests (Big Pharma and lobbied government officials) to cut corners so that drugs can get to market faster. So much for the efficacy of the FDA! So, you want more of the same?
lot of medical doctors are in the back pocket of Big Pharma, not to mention the AMA:
can go here to find out if your particular doctor is on the take:

This post was published at Gary North on March 25, 2017.

After Years of Price Gouging, Mylan’s EpiPen Gets Crushed

Under onslaught of new competition, monopoly status collapses.
Mylan’s EpiPen – the center of one of the many blistering scandals on Big Pharma price gouging – is getting hammered in the market, as competitors have burst on the scene, and as health insurers and prescribing physicians have gotten the memo. Its market share plunged from 95% to 71% in just two months!
Mylan had acquired the rights to the decades-old product in 2007. At the time, pharmacies were charged less than $100 for a two-pen set. By 2009, pharmacies were charged $103.50 for a set. Then the annual price hikes set in – ‘peaking every year in August, when parents of children with severe allergies typically stock up on the life-saving devices for use in schools.’
In 2016, the price spike hit $608.61 – an increase of over 500% in a decade. And this finally kicked off the uproar that landed Mylan CEO Heather Bresch on the hot seat before the House oversight committee hearing on EpiPen price increases.

This post was published at Wolf Street on Mar 7, 2017.

Mylan’s EpiPen Gets Crushed (by New Competition)

Market share collapses from a state of near-monopoly.
Mylan’s EpiPen – the center of one of the many blistering scandals on Big Pharma price gouging – is getting hammered in the market, as competitors have burst on the scene, and as health insurers and prescribing physicians have gotten the memo. Its market share plunged from 95% to 71% in just two months!
Mylan had acquired the rights to the decades-old product in 2007. At the time, pharmacies were charged less than $100 for a two-pen set. By 2009, pharmacies were charged $103.50 for a set. Then the annual price hikes set in – ‘peaking every year in August, when parents of children with severe allergies typically stock up on the life-saving devices for use in schools.’
In 2016, the price spike hit $608.61 – an increase of over 500% in a decade. And this finally kicked off the uproar that landed Mylan CEO Heather Bresch on the hot seat before the House oversight committee hearing on EpiPen price increases.

This post was published at Wolf Street on Mar 7, 2017.

These Numbers Prove Big Pharma Is Scared of Trump

After just a little over one month in office, President Donald Trump has successfully loosened the big pharma industry’s grip on exorbitant drug price increases.
January is traditionally the month that sees the highest list price hikes from prescription drugmakers. But on Feb. 27, The Wall Street Journal reported that pharma companies did not raise prices for as many drugs as last year and imposed fewer boosts of 10% or greater.
In fact, January saw the lowest increases of drug prices in three years, with hikes over 10% limited to just 5.5% – 15% fewer than in 2015.
The reason for the pullback: Big pharma execs are hoping to stay out of the spotlight at a time when President Trump has called for stronger Medicare authority in negotiating prices and a ‘total overhaul’ of the healthcare system.

This post was published at Wall Street Examiner on February 27, 2017.

Those Systems That Aren’t Busy Being Born Are Busy Dying

What we have is a bunch of sclerotic, dying institutions and systems resisting anything and everything that threatens to disrupt the status quo.
One way to understand the rising sense of disintegration and discord around the globe is to realize that those systems that aren’t busy being born are busy dying–and virtually none of our primary systems are busy being born. The line is from Bob Dylan’s song It’s Alright, Ma (I’m Only Bleeding): “he not busy being born is busy dying.” What does busy being born mean? For both individuals and systems, it means adapting by advancing understanding, flexibility and capabilities. Systems that are dying are rigid, mal-adapted, resistant to change, obsessed with obscuring their failure and retaining their grip on cronyist privilege and power. Big Pharma: dying. Banking: dying. Governance, a.k.a. political processes: dying. Enforced consensus: dying.

This post was published at Charles Hugh Smith on SUNDAY, FEBRUARY 26, 2017.

Drug Prices in the US vs. Canada – The Big Pharma Political Connection of Corporatist Democrats

This is a slide used by Bernie Sanders when he proposed making drug imports from Canada to the US legal.
The proposal was voted down in the Senate 52-46, with a few key Democrats helping overturn Bernie’s proposed legislation.
Among those voting against it was the recipient of big pharma campaign contributions Democratic rising star Cory Booker.
Booker used the Big Pharma talking point that ‘the bill did not include provisions requiring the protections of the FDA.’
Oh really? We think that the Canadian government’s regulation of medicine is weaker than in the US? Please, Cory, tell us exactly where they fall down on the job.


This post was published at Jesses Crossroads Cafe on 29 JANUARY 2017.